3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasm Metastasis
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Clear-cell metastatic renal cell carcinoma
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
Trastuzumab
3
pembrolizumab
2
Paclitaxel
2
Nivolumab
2
Interleukin-12 Subunit p35
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
seribantumab
1
sargramostim
1
pertuzumab
1
lenvatinib
1
entinostat
1
atezolizumab
1
Thalidomide
1
Specimen Handling
1
Psychiatric Rehabilitation
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Interleukin-12
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
lenvatinib
×
Genitourinary
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled